Oregon’s Legal Psilocybin Program Treated 346 People — Here’s What Happened

Nearly two-thirds of people who took psilocybin in a legal, supervised setting described the experience as one of the ten most meaningful of their lives. That finding comes not from a carefully screened clinical trial population, but from ordinary adults who walked through the doors of a licensed service center in Oregon, sat with a facilitator, and took a dose of mushroom-derived psilocybin.

The psilocybin therapy results that came back at three months covered depression, anxiety, PTSD, and life satisfaction – and across all four measures, the changes were substantial. The safety profile was largely reassuring, the limitations were real, and the data came from two dozen service centers rather than a single university lab.

Oregon became the first state in the nation to allow the use of psilocybin in a therapeutic setting after voters approved Ballot Measure 109 in November 2020. The measure directed the state’s health authority to build a licensing and regulatory framework from the ground up. Oregon officially became the first state with a functioning legal psilocybin system in 2023, with no requirement that participants have a diagnosed mental health condition.

What the Oregon program actually is

Unlike clinical trials, which use carefully selected participants, synthetic pharmaceutical psilocybin, and ongoing therapeutic support, the Oregon program allows any adult over 21 to participate for any reason, uses mushroom-derived products, and doesn’t require facilitators to have professional clinical training. That’s a meaningful departure from the research settings that generated the most-cited psilocybin data to date.

To formally evaluate how the program was performing, a research team led by Dr. Todd Korthuis, a professor of medicine at Oregon Health & Science University, launched an observational study under the Oregon Psychedelic Evaluation Nexus. The study enrolled 346 people who joined licensed facilitators for a single psilocybin session between November 2024 and June 2026. Participants reported their state of mind at baseline, one week, one month, and three months after their sessions, drawn from 24 licensed service centers across Oregon.

The OHSU-led study is the largest study of psychedelics conducted outside clinical trial settings. The findings were published in JAMA Network Open in August 2026.

The psilocybin therapy results: depression, anxiety, and PTSD

At one month, 91.5% of participants reported they had benefited from the experience, and 64.9% ranked it among the ten most meaningful of their lives.

By the three-month follow-up, the changes in clinical symptom measures were substantial across all three major mental health domains the study tracked. According to the study published in JAMA Network Open, the proportion of participants reporting moderate-to-severe PTSD symptoms fell from 48% before treatment to 16.8% at three months. Anxiety followed a similar arc: moderate-to-severe symptoms dropped from 45.1% of the cohort to 13.2%. Depression declined from 42.2% to 16.5% over the same period. Life satisfaction, measured separately, climbed from 63% to 82.3% across the group.

The average dose participants received was approximately 31.9 milligrams, though individual doses ranged from as low as 2 milligrams to as high as 50 milligrams, depending on facilitator guidance and client preference.

Dr. Korthuis was measured in how he framed the results. “Safety was very similar to what we’ve seen with psychedelics in clinical settings,” he said. “That’s important because there was a big question around whether safety in carefully controlled psilocybin clinical trials would translate into real-world use.”

Adrianne R. Wilson-Poe, a neuroscientist at the Legacy Research Institute and co-director of the Oregon Psychedelic Evaluation Nexus, described the study’s significance directly. “This paper is going to be cited for decades,” she said. “This is the first large-scale study to monitor the safety and mental health symptoms of real people in the real world.”

The safety profile and its limitations

Most participants experienced no serious adverse events. Four people experienced adverse behavioral reactions that required medical attention, representing 1.2% of the cohort. One person became violent and was transported to the hospital. A second reported an emergency room visit, worsening anxiety and depression, and thoughts of self-harm. A third reported an emergency room visit and worsening anxiety and depression. The fourth reported severe anxiety and insomnia requiring medication, along with worsening symptoms and thoughts of self-harm that persisted through the three-month mark.

All four shared a set of characteristics. All were psychedelic-naive, meaning they had never taken a psychedelic before, and all had pre-existing symptoms of depression, anxiety, or PTSD. They also received relatively high doses, ranging from 25 to 50 milligrams.

The researchers noted that inexperience with psychedelics, greater psychological vulnerability, and higher doses may increase the risk of serious reactions, though four cases are too few to establish that as a firm conclusion. Among the full cohort, no participants reported a serious event related to their physical health. The safety profile emerging from Oregon is notable partly because of how different this population is from clinical trial participants. People in tightly controlled trials are screened extensively, often excluding those with certain psychiatric histories, and they receive consistent professional therapeutic support before and after dosing. Oregon’s program has none of those filters.

Why this study is different from what came before

For decades, psilocybin research happened almost entirely inside university labs and federally approved clinical trials, with narrow participant pools and strict protocols. The OHSU study was conducted in collaboration with researchers from the VA Portland Health Care System, the Portland Institute for Psychedelic Science, New York University, and the Legacy Research Institute – a notably broad coalition for a study of this type.

Oregon’s real-world data now runs in parallel to the ongoing federal regulatory process, providing something clinical trials structurally cannot: evidence of what happens when access is open, doses vary, and participants aren’t pre-screened.

Participants reported through a web-based portal, and 90% continued to do so through the full three months – an unusually high retention rate for a real-world study with no financial incentive for continued participation.

What the limitations mean for anyone reading these results

The study’s authors were transparent about what the data cannot tell us. There was no control group, which means the improvements observed could reflect the natural passage of time, placebo response, expectation effects, or the simple fact that people who voluntarily seek out a novel wellness experience may differ systematically from those who don’t. The participants were, on the whole, healthier and wealthier than the average Oregonian. Most were white. Only around 5% of Oregon’s total psilocybin client base during the study period participated in the study.

That self-selection matters. People who sign up for observational research after taking psilocybin may be more likely to have had positive experiences than those who don’t volunteer. Serious adverse reactions in clients who don’t enroll in studies might never be captured in the data.

“This may be a reflection of clients who were healthier overall than clinical trial participants,” Korthuis acknowledged. That context doesn’t invalidate the findings – it shapes how much weight any individual reader should place on them.

What this means for you

Psilocybin remains a federally controlled substance in the U.S., and the Oregon program is the only functioning state-regulated legal framework of its kind in the country. Anyone outside Oregon considering psilocybin therapy does not currently have legal access to a regulated program. For those in Oregon, the data suggests that first-time users with existing psychiatric symptoms should discuss dose selection carefully with their facilitator, given that the four serious adverse events in this study all involved psychedelic-naive individuals at higher doses.

For people managing treatment-resistant depression, anxiety, or PTSD who are watching this space: the Oregon psilocybin therapy results represent the most rigorous real-world data available. The symptom reductions – moderate-to-severe PTSD falling from 48% to 16.8%, anxiety from 45.1% to 13.2%, and depression from 42.2% to 16.5% over three months – are larger than what most conventional treatments achieve in similar timeframes, though the absence of a control group means direct comparison is limited. The adverse event rate in an unscreened population was lower than many researchers anticipated.

Anyone with existing mental health conditions, a history of psychosis, or who takes psychiatric medications should speak with a physician before pursuing any psilocybin service, even in a legal, licensed setting.

Disclaimer: The information provided here is for educational and informational purposes only and is not a substitute for professional psychological, psychiatric, or mental health advice, diagnosis, or treatment. Always seek the guidance of a licensed mental health professional, therapist, psychologist, or psychiatrist with any questions or concerns about your emotional well-being or mental health conditions. Never ignore professional advice or delay seeking support because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.

Read More: Mild Head Trauma Reversed in Rats with Psilocybin Treatment